Mach7 Technologies Limited

The Business

Mach7 sells vendor-neutral archive (VNA) software that lets hospitals store and retrieve medical images, X-rays, CT and MRI scans, independent of which imaging hardware or electronic health record system a hospital runs. About 86% of revenue comes from the United States, sold mostly as annual subscriptions rather than one-off licences, which is why 84% of FY26 revenue was recurring. The business is a single segment with minimal hardware and a cost base that is 85% fixed, so once revenue clears a threshold, most incremental sales dollars should drop straight to profit.

Recent Performance

Revenue fell 17.5% in FY26 to $27.9 million, down from $33.8 million, after two enterprise customers (Trinity Health and VHA) exited and one-off licence sales continued their scheduled decline. Management cut operating costs by roughly 16% and installed an almost entirely new senior team, with seven of eight executives holding under 12 months in the role. The FY26 loss per share was 3.8 cents. The shares currently trade at $0.285, a level that presumes the restructuring will succeed in reigniting growth.

Outlook

We expect revenue growth to resume over the next three years as subscription revenue continues to compound and the shrinking one-off licence line fades toward zero, though the pace of recovery is modest rather than dramatic. Gross margin should hold near 93%, but rising operating costs mean earnings before interest, tax, depreciation and amortisation (EBITDA) are only expected to turn positive later in the forecast window, and even then at a thin margin relative to mature software peers. The net loss is expected to narrow progressively but persist throughout the forecast period, meaning Mach7 remains a pre-profit business for the foreseeable future on our numbers.

Key Risks

Mach7 has never converted its high gross margins into profit across several management teams, and persistence of that pattern would confirm the business is subscale rather than merely early in a turnaround. The current senior team, in place under 12 months for seven of eight executives, must simultaneously fix customer retention, reignite growth and launch a new product with no shared track record together, a combination that carries meaningful execution risk. A further enterprise customer loss, following the two departures in FY26, would reset the recovery timeline against a cost base that is only narrowly above breakeven.

What to Watch

The thesis-defining event is the H1 FY27 result in February 2027, the first clean half under the restructured cost base, which will show whether annual recurring revenue growth is accelerating or stalling.

• Nov-Dec 2026 RSNA 2026 Flamingo customer announcements — new customer wins for the AI orchestration platform would validate the growth thesis beyond cost-cutting.
• 12-36 months PE-backed M&A interest in imaging IT consolidation — an acquisition approach would test the market's standalone assumptions for the business.

Company Description

Mach7 Technologies builds enterprise imaging software used by hospitals to store, manage and share medical images. The core product is a vendor-neutral archive, meaning it works across different imaging hardware and electronic health record systems rather than locking hospitals into one vendor's ecosystem. Revenue splits into three lines: recurring subscription revenue ($23.4 million in FY26, 84% of the total), one-off capital licence sales for on-premises deployments (shrinking toward zero as the business shifts to subscriptions), and professional services for implementation ($3.0 million). Roughly 86% of revenue is generated in the United States, with the balance spread across smaller international markets.

Where the Growth Is

The company's next growth leg is Flamingo, an AI and data orchestration platform that sits on top of the core archive and routes imaging data to AI diagnostic tools. It currently has one live customer and contributes negligible revenue. The November-December 2026 RSNA industry conference is the key validation point: if Flamingo lands three or more enterprise customers within 24 months, it would represent a genuine second growth engine beyond the core archive business. Until then, it remains an early-stage bet rather than a demonstrated revenue driver.

Competitive Position

Mach7's advantage rests on two pillars: vendor-neutral positioning that appeals to hospitals wary of being locked into a single imaging supplier, and switching costs embedded in multi-year enterprise contracts, since migrating archived medical images to a new vendor is slow, expensive and clinically sensitive. That combination has kept 84% of revenue recurring and multi-year in nature. It has not, however, translated into market share gains: Mach7 holds under 1% of the global imaging IT market, a position that has been stable rather than expanding. Larger rivals such as Sectra, Hyland and Intelerad spend far more on research and sales, which caps Mach7's ability to win share even where its technology competes well. The advantage is durable for perhaps five to seven years but requires continuous execution to defend, not a moat that widens on its own.

Management & Capital Discipline

Management has kept the balance sheet conservative: zero debt and a preserved $19.9 million cash position, funding well over a decade of operations at the current burn rate. A share buyback completed at higher prices in prior years was poorly timed in hindsight, reducing the cash cushion available today. The clearest achievement is cost discipline: the roughly 16% reduction in operating expenses is verified in the FY26 accounts and has taken the business to within roughly $0.8 million of EBITDA breakeven. What remains unproven is growth. The senior team delivering these cuts has, for the most part, been in place under 12 months, and the harder task, reigniting revenue growth, has no track record yet under this leadership.

Financial Position

The balance sheet is the company's strongest asset. Mach7 carries no debt, holds $19.9 million in cash, and its subscription billing structure means customers pay in advance, so working capital is structurally negative and does not consume cash as the business grows. At the current burn rate of roughly $1 to 2 million a year, cash covers more than ten years of operations even without any improvement in trading, giving ample room to absorb further setbacks without raising capital or taking on debt.